Current Neuro-Oncology

Volume 13 Number 12
31 December 2011

Home > Publications > Current Neuro-Oncology > Volume 13, Year 2011 > Number 12, 31 December

Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH.
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.
J Med Genet. 2011 Dec;48(12):856-9
. doi: 10.1136/jmedgenet-2011-100156. Epub 2011 Sep 22. PMID: 21941004. Laboratory investigation.

Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I.
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.
Pediatr Blood Cancer. 2011 Dec 6. 2012;59(3):511-7. doi: 10.1002/pbc.24006
. PMID: 22147459. Retrospective analysis & Phase 2 trial.

Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M.
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.
Neuro Oncol. 2011 Dec 6. 2012 Feb;14(2):222-9. doi: 10.1093/neuonc/nor200
. PMID: 22146386. Retrospective analysis.

Villano JL, Letarte N, Bressler LR.
Going past the data for temozolomide.
Cancer Chemother Pharmacol. 2011 Dec 7. 2012;69(4):1113-5. doi: 10.1007/s00280-011-1796-4
. PMID: 22147076. Comment.
Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol. 2009 Mar 9. 2009;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. PMID: 19269895. Phase 3 trial.

Mason WP, Macneil M, Kavan P, Easaw J, Macdonald D, Thiessen B, Urva S, Lwin Z, McIntosh L, Eisenhauer E.
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Invest New Drugs. 2011 Dec 9. 2012;30(6):2344-51. doi: 10.1007/s10637-011-9775-5. PMID: 22160854. Phase 1 trial.

Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB.
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro Oncol. 2010 Dec 10. 2011;13(3):324-33. doi: 10.1093/neuonc/noq157
. PMID: 21149254. Phase 2 trial.

Nygaard R, Kivivuori SM.
Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Anticancer Drugs. 2011 Dec 12. 2012;23(3):342-6. doi: 10.1097/CAD.0b013e32834ee315. PMID: 22156796. Case report.

McBride WH.
Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma.
Future Oncol. 2011 Dec 13. 2012;8(1):17-20. doi: 10.2217/fon.11.126. PMID: 22149031. Comment.
Chiocca EA, et al.
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

J Clin Oncol. 2011 Aug 15. 2011;29(27):3611-9. doi: 10.1200/JCO.2011.35.5222. PMID: 21844505. Phase 1B trial.

Tsai HC, Wei KC, Tsai CN, Huang YC, Chen PY, Chen SM, Lu YJ, Lee ST.
Effect of valproic acid on the outcome of glioblastoma multiforme.
Br J Neurosurg. 2011 Dec 15. 2012;26(3):347-54. doi: 10.3109/02688697.2011.638996. PMID: 22168970. Retrospective analysis.

van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J.
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Oncotarget. 2011 Dec 15. 2011;2(12):984-96. doi: 10.18632/oncotarget.362
. PMID: 22184287. Laboratory investigation.

Koga T, Maruyama K, Tanaka M, Ino Y, Saito N, Nakagawa K, Shibahara J, Todo T.
Extended field stereotactic radiosurgery for recurrent glioblastoma.
Cancer. 2011 Dec 16. 2012;118(17):4193-200. doi: 10.1002/cncr.27372. PMID: 22180028. Case series.

Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, Shen X, Symon Z, Dicker AP.
Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
Cancer. 2011 Dec 16. 2012 Sep 1;118(17):4228-34. doi: 10.1002/cncr.26685. PMID: 22180310. Retrospective analysis.

Murakami R, Hirai T, Nakamura H, Furusawa M, Nakaguchi Y, Uetani H, Kitajima M, Yamashita Y.
Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval.
Jpn J Radiol. 2011 Dec 20. 2012 Apr;30(3):193-7. doi: 10.1007/s11604-011-0031-x. PMID: 22183828. Clinical study.

Zhuang W, Long L, Zheng B, Ji W, Yang N, Zhang Q, Liang Z.
Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy.
Cancer Sci. 2011 Dec 22. 2012;103(4):684-90. doi: 10.1111/j.1349-7006.2011.02198.x
. PMID: 22192169. Laboratory investigation.

Kilickap S, Oztoprak I, Yucel B.
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Acta Oncol. 2011 Dec 27. 2012;51(4):544-6. doi: 10.3109/0284186X.2011.644251
. PMID: 22201408. Case report.